A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : BAL / British anti-lewisite

[Related PubMed/MEDLINE]
Total Number of Papers: 45
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   BAL  (>> Co-occurring Abbreviation)
Long Form:   British anti-lewisite
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2018 Interaction of Arsenous Acid with the Dithiol-Type Chelator British Anti-Lewisite (BAL): Structure and Stability of Species Formed in an Unexpectedly Complex System. ---
2016 One step derivatization with British Anti-Lewsite in combination with gas chromatography coupled to triple-quadrupole tandem mass spectrometry for the fast and selective analysis of inorganic arsenic in rice. iAs
2016 Reversible oxidation of vicinal-thiols motif in sarcoplasmic reticulum calcium regulatory proteins is involved in muscle fatigue mechanism. PAO, RyR, SM, SR, VTG
2013 Cholestasis and seizure due to lead toxicity: a case report. EDTA, MRCP
2013 The role of chelation in the treatment of arsenic and mercury poisoning. ---
2008 Heavy metal induced oxidative stress & its possible reversal by chelation therapy. DMPS, DMSA
2007 Arsenic and lead induced free radical generation and their reversibility following chelation. CNS, DMSA
2007 Arsenic induced oxidative stress and the role of antioxidant supplementation during chelation: a review. DMPS, DMSA
2004 Effects of antirheumatic gold compounds on the conversion of xanthine dehydrogenase to oxidase in rabbit liver cytosol in vitro. AUR, AuTG, AuTM, NAC, XD
10  2004 Gas chromatographic-mass spectrometric determination of british anti-lewisite in plasma. CV, IS
11  2003 British anti-Lewisite (dimercaprol): an amazing history. ---
12  2002 Arsenate reductase II. Purine nucleoside phosphorylase in the presence of dihydrolipoic acid is a route for reduction of arsenate to arsenite in mammalian systems. DHLP, PNP
13  1999 Cadmium therapeutic agents. EDTA, IARC
14  1996 Biochemical and immunotoxicological alterations following repeated gallium arsenide exposure and their recoveries by meso-2,3-dimercaptosuccinic acid and 2,3-dimercaptopropane 1-sulfonate administration in rats. AFC, ALAD, DMPS, DMSA, DTH, GaAs
15  1995 Pediatric arsenic ingestion. DMSA, DP
16  1994 Effect of various antidotes on the biliary and intestinal excretion of arsenic in situ and into the feces in vivo in guinea-pigs after injection of As2O3. BAPSA, DMPS, DMSA
17  1994 Potential problems in using [35S]-dATP-tailed oligonucleotides for detecting mRNAs in certain cells of the immune system. ---
18  1991 Arsenic intoxication presenting as a myelodysplastic syndrome: a case report. ---
19  1991 Inhibition of muscarinic cholinergic receptors by disulfide reducing agents and arsenicals. Differential effect on locust and rat. DTT, PCMB
20  1991 Pyruvate and lactate metabolism in livers of guinea pigs perfused with chelating agents after repeated treatment with As2O3. BAPSA, DMPS, DMSA
21  1990 Arsenic distribution in rabbits after Lewisite administration and treatment with British anti-Lewisite (BAL). ---
22  1990 Polyneuropathy due to acute arsenic intoxication: biopsy studies. LAMMA
23  1990 Treating exposure to chemical warfare agents: implications for health care providers and community emergency planning. ---
24  1986 Rapid redox equilibrium between the mitochondrial Q pool and cytochrome b during triphasic reduction of cytochrome b by succinate. ---
25  1984 N-(2,3-dimercaptopropyl)phthalamidic acid: protection, in vivo and in vitro, against arsenic intoxication. DMPA, PDH
26  1982 [Reduction of dehydroascorbic acid by thiols in presence of biocatalytic substances: polarographic study]. ---
27  1972 British anti-lewisite (BAL), the classic heavy metal antidote. ---
28  1956 Glucosuria in rats receiving British anti-lewisite (BAL). ---
29  1955 [Effects of BAL (British anti lewisite) on sublimate poisoning]. ---
30  1955 [Latest experimental research on the action of BAL (British anti-lewisite) in sublimate poisoning]. ---
31  1951 [BAL (British anti-lewisite) and its antidotal action in phosphorus, zinc and zinc phosphide poisoning]. ---
32  1950 The use of British anti-lewisite (BAL) in the treatment of diabetic neuropathy; clinical study; preliminary report. ---
33  1948 BAL (British anti-lewisite). ---
34  1947 BAL (British anti-lewisit) as an antidote to poisoning with inorganic arsenic. ---
35  1947 British anti-lewisite (BAL). ---
36  1947 The action of British anti-lewisite (BAL) on enzyme systems. ---
37  1947 The fate of arsenical vesicants in the skin and the effect of BAL (British anti-lewisite). ---
38  1947 The treatment of lewisite and other arsenical vesicant lesions of the eyes of rabbits with British anti-lewisite (BAL). ---
39  1946 BAL (British anti-lewisite) in the treatment of arsenic and mercury poisoning. ---
40  1946 BRITISH anti-lewisite (BAL). ---
41  1946 Canadian Researches on BAL (British Anti-Lewisite). ---
42  1946 Canadian researches on BAL (British anti-lewisite). ---
43  1946 Clinical uses of 2,3-dimercaptopropanol (BAL); the treatment of complications of arseno-therapy with BAL (British anti-lewisite). ---
44  1946 The therapeutic effects of British anti-lewisite (BAL) on tissue cultures grown in a medium containing lewisite oxide. ---
45  1945 British anti-lewisite (BAL). ---